Professur für Rheumatologie und Klinische Immunologie

Gout, hyperuricaemia and crystal-associated disease network (G-CAN) consensus statement regarding labels and definitions of disease states of gout (2019) Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, et al. Journal article Cost-effective tapering algorithm in patients with rheumatoid arthritis: Combination of multibiomarker disease activity score and autoantibody status (2019) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Journal article THE PROGNOSIS OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS (2018) Meissner Y, Schaefer M, Manger B, Zaenker M, Ochs W, Listing J, Strangfeld A Conference contribution Neutrophilic Dermatoses - Classification and Pathophysiology (2018) Manger B Journal article Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS (2018) Sauer EM, Schliep S, Manger B, Lee DH, Linker R Journal article LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION-IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION (2018) Erhard J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study (2018) Guilhon de Araujo E, Englbrecht M, Höpken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, et al. Journal article ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY (2017) Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study (2017) Guilhon de Araujo E, Englbrecht M, Höpken S, Finzel S, Hueber A, Rech J, Schett G Conference contribution MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Conference contribution